(Q42165477)

17 October 2017

title

Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma (English)

1 reference

17 October 2017

1 reference

A P Rapoport

1

1 reference

17 October 2017

C Guo

2

1 reference

17 October 2017

A Badros

3

1 reference

17 October 2017

R Hakimian

4

1 reference

17 October 2017

G Akpek

5

1 reference

17 October 2017

E Kiggundu

6

1 reference

17 October 2017

B Meisenberg

7

1 reference

17 October 2017

H Mannuel

8

1 reference

17 October 2017

N Takebe

9

1 reference

17 October 2017

R Fenton

10

1 reference

17 October 2017

J Bolaños-Meade

11

1 reference

17 October 2017

M Heyman

12

1 reference

17 October 2017

I Gojo

13

1 reference

17 October 2017

K Ruehle

14

1 reference

17 October 2017

S Natt

15

1 reference

17 October 2017

B Ratterree

16

1 reference

17 October 2017

T Withers

17

1 reference

17 October 2017

C Sarkodee-Adoo

18

1 reference

17 October 2017

G L Phillips

19

1 reference

17 October 2017

G Tricot

20

1 reference

17 October 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Bone Marrow Transplantation

17 October 2017

published in

1 reference

17 October 2017

volume

34

1 reference

17 October 2017

issue

10

1 reference

17 October 2017

page(s)

883-890

1 reference

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

17 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in pat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Intensive therapy and autotransplantation in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

An information-intensive approach to the molecular pharmacology of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: cost, safety, and long-term efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

Antiapoptosis potential of bcl-2 oncogene by dephosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

A case of primary refractory Hodgkin's disease treated successfully with paclitaxel

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704661

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704661

1 reference

Dimensions Publication ID

17 October 2017

1007814360

0 references

1 reference